Are PANCA, ASCA, or Cytokine Gene Polymorphisms Associated with Pouchitis? Long-term Follow-up in 102 Ulcerative Colitis Patients
Overview
Authors
Affiliations
Objective: Pouchitis is the most frequent complication after ileal pouch-anal anastomosis for ulcerative colitis. This study aims to analyze the frequency and characteristics of pouchitis in long-term follow-up in a large population, and to determine whether a significant association exists between five immunogenetic markers and pouchitis.
Methods: From a population of over 500 ulcerative colitis patients who had undergone ileal pouch-anal anastamosis 5-12 yr earlier, 102 subjects participated in the study. Using clinical data obtained from interviews and chart reviews, patients were classified into three groups: no pouchitis; 1-2 episodes per year; and >2 episodes per year. Coded sera from the patients were analyzed for ulcerative colitis-associated perinuclear antineutrophil cytoplasmic antibodies and Crohn's disease-associated anti-saccharomyces cerevesiae antibodies. Interleukin-1 receptor antagonist, tumor necrosis factor (TNF), and lymphotoxin beta (lymphotoxin) polymorphisms were also analyzed.
Results: Pouchitis affected 49% of the study population. Antineutrophil cytoplasmic antibodies, anti-saccharomyces cerevesiae antibodies, and lymphotoxin-beta polymorphisms were not associated with pouchitis. Carriage of interleukin-1 receptor antagonist allele 2 was significantly greater among those without pouchitis than those with pouchitis. Patients without pouchitis had a significantly greater carriage rate of TNF allele 2.
Conclusions: Perinuclear antineutrophil cytoplasmic antibodies and anti-saccharomyces cerevesiae antibodies are not correlated with pouchitis, but interleukin-1 receptor antagonist and TNF may play a role in its development. Further evaluation of these markers in pouchitis will require larger populations, long-term prospective observation, and studies that correlate polymorphisms with specific immunologic functions.
The aetiology of pouchitis in patients with inflammatory bowel disease.
Alenzi M, Schildkraut T, Hartley I, Badiani S, Ding N, Rao V Therap Adv Gastroenterol. 2024; 17:17562848241249449.
PMID: 38812704 PMC: 11135114. DOI: 10.1177/17562848241249449.
Disease Monitoring of the Ileoanal Pouch: How to Utilize Biomarkers, Imaging, and Pouchoscopy.
Barnes E, Darlington K, Herfarth H Curr Gastroenterol Rep. 2022; 24(11):127-136.
PMID: 36255602 DOI: 10.1007/s11894-022-00850-9.
Pouchitis: insight into the pathogenesis and clinical aspects.
de Negreiros L, Pascoal L, Genaro L, Silva J, Rodrigues B, Camargo M Am J Transl Res. 2022; 14(7):4406-4425.
PMID: 35958439 PMC: 9360866.
Medical management of chronic pouch inflammation.
Kayal M, Dubinsky M Curr Res Pharmacol Drug Discov. 2022; 3:100095.
PMID: 35281692 PMC: 8913311. DOI: 10.1016/j.crphar.2022.100095.
Review article: the pathogenesis of pouchitis.
Schieffer K, Williams E, Yochum G, Koltun W Aliment Pharmacol Ther. 2016; 44(8):817-35.
PMID: 27554912 PMC: 5785099. DOI: 10.1111/apt.13780.